Mediators of Inflammation
Volume 2006 (2006), Article ID 39062, 7 pages
doi:10.1155/MI/2006/39062
Research Communication

Evaluation of Tumour Necrosis Factor Alpha, Interleukin-2 Soluble Receptor, Nitric Oxide Metabolites, and Lipids as Inflammatory Markers in Type 2 Diabetes Mellitus

Flávia Ozorio Pereira,1 Tânia Silvia Frode,2 and Yara Santos Medeiros1,3

1Diabetes Unit, Governador Celso Ramos Hospital, Florianópolis, Santa Catarina 88020-30, Brazil
2Department of Clinical Analysis, Sciences, and Health Center, Federal University of Santa Catarina, Florianópolis, Santa Catarina 88040-970, Brazil
3Department of Pharmacology, Center of Biological Sciences, Federal University of Santa Catarina, Florianópolis, Santa Catarina 88049-900, Brazil

Received 25 August 2005; Accepted 13 October 2005

Copyright © 2006 Flávia Ozorio Pereira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “United Kingdom Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33),” Lancet, vol. 352, no. 9131, pp. 837–853, 1998. View at Publisher · View at Google Scholar · View at PubMed
  2. “Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III),” JAMA: The Journal of the American Medical Association, vol. 285, no. 19, pp. 2486–2497, 2001. View at Publisher · View at Google Scholar · View at PubMed
  3. “The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus,” The New England Journal of Medicine, vol. 329, no. 14, pp. 977–986, 1993. View at Publisher · View at Google Scholar · View at PubMed
  4. “American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 27, no. suppl 1, pp. S5–S10, 2004. View at PubMed
  5. L C Green, D A Wagner, J Glogowski, P L Skipper, J S Wishnok, and S R Tannenbaum, “Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids,” Analytical Biochemistry, vol. 126, no. 1, pp. 131–138, 1982. View at Publisher · View at Google Scholar · View at PubMed
  6. M Di Rosa, A Ialenti, A Ianaro, and L Sautebin, “Interaction between nitric oxide and cyclooxygenase pathways,” Prostaglandins, Leukotrienes, and Essential Fatty Acids, vol. 54, no. 4, pp. 229–238, 1996. View at Publisher · View at Google Scholar · View at PubMed
  7. G Ellis, I Adatia, M Yazdanpanah, and S K Makela, “Nitrite and nitrate analyses: a clinical biochemistry perspective,” Clinical Biochemistry, vol. 31, no. 4, pp. 195–220, 1998. View at Publisher · View at Google Scholar · View at PubMed
  8. M E Molitch, R A DeFronzo, M J Franz, et al., “Nephropathy in diabetes,” Diabetes Care, vol. 27, no. suppl 1, pp. S79–S83, 2004. View at PubMed
  9. P M Ridker, “Clinical application of C-reactive protein for cardiovascular disease detection and prevention,” Circulation, vol. 107, no. 3, pp. 363–369, 2003. View at Publisher · View at Google Scholar · View at PubMed
  10. I J Jonkers, M F Mohrschladt, R G Westendorp, A van der Laarse, and A H Smelt, “Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial,” The American Journal of Medicine, vol. 112, no. 4, pp. 275–280, 2002. View at Publisher · View at Google Scholar · View at PubMed
  11. P M Ridker, N Rifai, M Pfeffer, F Sacks, S Lepage, and E Braunwald, “Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction,” Circulation, vol. 101, no. 18, pp. 2149–2153, 2000. View at PubMed
  12. B M Matata and M Galinanes, “Effect of diabetes on nitric oxide metabolism during cardiac surgery,” Diabetes, vol. 50, no. 11, pp. 2603–2610, 2001. View at PubMed
  13. S Ozden, S Tatlipinar, N Bicer, et al., “Basal serum nitric oxide levels in patients with type 2 diabetes mellitus and different stages of retinopathy,” Canadian Journal of Ophthalmology, vol. 38, no. 5, pp. 393–396, 2003. View at PubMed
  14. F Chiarelli, F Cipollone, F Romano, et al., “Increased circulating nitric oxide in young patients with type 1 diabetes and persistent microalbuminuria: relation to glomerular hyperfiltration,” Diabetes, vol. 49, no. 7, pp. 1258–1263, 2000. View at PubMed
  15. A Aydin, H Orhan, A Sayal, M Ozata, G Sahin, and A Isimer, “Oxidative stress and nitric oxide related parameters in type II diabetes mellitus: effects of glycemic control,” Clinical Biochemistry, vol. 34, no. 1, pp. 65–70, 2001. View at Publisher · View at Google Scholar · View at PubMed
  16. P M Piatti, L D Monti, I Zavaroni, et al., “Alterations in nitric oxide/cyclic-GMP pathway in nondiabetic siblings of patients with type 2 diabetes,” The Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 7, pp. 2416–2420, 2000. View at Publisher · View at Google Scholar · View at PubMed
  17. S Doganay, C Evereklioglu, H Er, et al., “Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus,” Eye, vol. 16, no. 2, pp. 163–170, 2002. View at Publisher · View at Google Scholar · View at PubMed
  18. F M Castillo, T A Romero, J Estévez, et al., “Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases,” Clinical and Diagnostic Laboratory Immunology, vol. 9, no. 6, pp. 1372–1375, 2002. View at Publisher · View at Google Scholar · View at PubMed
  19. M Coutinho, H C Gerstein, Y Wang, and S Yusuf, “The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years,” Diabetes Care, vol. 22, no. 2, pp. 233–240, 1999. View at PubMed
  20. S M Haffner, S Lehto, T Ronnemaa, K Pyorala, and M Laakso, “Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction,” The New England Journal of Medicine, vol. 339, no. 4, pp. 229–234, 1998. View at Publisher · View at Google Scholar · View at PubMed
  21. H Nakae, S Endo, M Kikuchi, et al., “Nitrite/nitrate (NOx) levels and hemodynamics during septic shock,” Surgery Today, vol. 30, no. 8, pp. 683–688, 2000. View at Publisher · View at Google Scholar · View at PubMed
  22. I Gustafsson, B Brendorp, M Seibaek, et al., “Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure,” Journal of the American College of Cardiology, vol. 43, no. 5, pp. 771–777, 2004. View at Publisher · View at Google Scholar · View at PubMed
  23. J Calles-Escandon and M Cipolla, “Diabetes and endothelial dysfunction: a clinical perspective,” Endocrine Reviews, vol. 22, no. 1, pp. 36–52, 2001. View at Publisher · View at Google Scholar · View at PubMed
  24. J Danesh, J G Wheeler, G M Hirschfield, et al., “C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease,” The New England Journal of Medicine, vol. 350, no. 14, pp. 1387–1397, 2004. View at Publisher · View at Google Scholar · View at PubMed
  25. J K Wolford, J D Gruber, V M Ossowski, et al., “A C-reactive protein promoter polymorphism is associated with type 2 diabetes mellitus in Pima Indians,” Molecular Genetics and Metabolism, vol. 78, no. 2, pp. 136–144, 2003. View at Publisher · View at Google Scholar · View at PubMed
  26. M B Schulze, E B Rimm, T Li, N Rifai, M J Stampfer, and F B Hu, “C-reactive protein and incident cardiovascular events among men with diabetes,” Diabetes Care, vol. 27, no. 4, pp. 889–894, 2004. View at PubMed
  27. P M Ridker, N Rifai, L Rose, J E Buring, and N R Cook, “Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events,” The New England Journal of Medicine, vol. 347, no. 20, pp. 1557–1565, 2002. View at Publisher · View at Google Scholar · View at PubMed
  28. G K Hansson, “Inflammation, atherosclerosis, and coronary artery disease,” The New England Journal of Medicine, vol. 352, no. 16, pp. 1685–1695, 2005. View at Publisher · View at Google Scholar · View at PubMed
  29. C M Norris, W A Ghali, P D Galbraith, M M Graham, L A Jensen, and M L Knudtson, “Women with coronary artery disease report worse health-related quality of life outcomes compared to men,” Health and Quality of Life Outcomes, vol. 2, no. 1, p. 21, 2004. View at Publisher · View at Google Scholar · View at PubMed
  30. K M King, W A Ghali, P D Faris, et al., “Sex differences in outcomes after cardiac catheterization: effect modification by treatment strategy and time,” JAMA: The Journal of the American Medical Association, vol. 291, no. 10, pp. 1220–1225, 2004. View at Publisher · View at Google Scholar · View at PubMed
  31. M Laakso and S Lehto, “Epidemiology of macrovascular disease in diabetes,” Diabetes Reviews, vol. 5, no. 4, pp. 294–315, 1997.
  32. T C Smitherman and S E Reis, “Heart disease in women with diabetes,” Diabetes Spectrum, vol. 10, no. 3, pp. 207–215, 1997.